Pharmaceutical - Pharmaceutical, Zambon

Filter

Current filters:

PharmaceuticalZambon

Popular Filters

Newron and Zambon re-submit NDA for safinamide following Refusal to File

Newron and Zambon re-submit NDA for safinamide following Refusal to File

29-12-2014

Clinical-stage biopharma company Newron and its commercial development partner, fellow Italy-based pharma…

NeurologicalNewron PharmaPharmaceuticalRegulationsafinamideUSAZambon

Milestone for Skyepharma as Flutiform debuts in Spain; and as Abriff in Italy

Milestone for Skyepharma as Flutiform debuts in Spain; and as Abriff in Italy

01-12-2014

UK oral and inhalation drug specialist Skyepharma says that, following regulatory approval and agreement…

AbriffFinancialFlutiformItalyJapanKyorin PharmaceuticalMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharmaSpainZambon

Newron and Zambon file safinamide NDA with FDA

Newron and Zambon file safinamide NDA with FDA

30-05-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

NeurologicalNewron PharmaPharmaceuticalRegulationsafinamideUSAZambon

Safinamide marketing application submitted to Swissmedic

07-04-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

Newron and Zambon file for EU approval of Parkinson’s drug safinamide

09-12-2013

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

EuropeNeurologicalNewron PharmaNorth AmericaPharmaceuticalRegulationsafinamideZambon

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Zambon to acquire UK respiratory specialist Profile Pharma

10-06-2013

Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

Newron executes safinamide deal with Zambon; new Ph III data; management changes

15-05-2012

In what was a busy news day for Italian drug developer Newron Pharmaceuticals SpA (SIX: NWRN), the company…

FinancialLicensingManagementNeurologicalNewron PharmaPharmaceuticalResearchsafinamideZambon

Newron licenses safinamide to Zambon for EU and USA

09-04-2012

Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration…

LicensingMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalsafinamideZambon

Back to top